BeiGene Co.,Ltd

236 articles with BeiGene Co.,Ltd

• BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021

  6/11/2021

  BeiGene, Ltd. announced long-term follow-up results from three pivotal trials in its hematology program at the 26th EHA 2021 Virtual Congress, including a pivotal Phase 2 trial of its anti-PD-1 antibody tislelizumab in relapsed or refractory classical Hodgkin’s lymphoma in an oral presentation, and two pivotal Phase 2 trials of its BTK inhibitor BRUKINSA® in R/R mantle cell lymphoma and in R/R chronic lymphocytic leukemia or small lymphocytic lymphoma in poster presentations.

• BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

  6/11/2021

  BeiGene, Ltd. presented results from the interim analysis of the Phase 3 ALPINE trial comparing its BTK inhibitor BRUKINSA® to ibrutinib in adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, including superiority in the primary endpoint of investigator-assessed overall response rate and superiority in a key secondary endpoint of atrial fibrillation or flutter.

• 

  BeiGene Presents Positive Data in Various Lymphomas at EHA2021

  6/11/2021

  Beigene presented results from three pivotal trials at the 26th EHA2021 Virtual Congress for the effectiveness of their checkpoint inhibitor tislelizumab in relapsed or refractory lymphoma.
• 

  Five Collaborations Unlocking Faster Drug Development this Week

  6/10/2021

  This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace takes a look at some of these announcements.

• BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors

  6/7/2021

  BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High or Mis-match Repair-Deficient Solid Tumors.

• BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting

  6/4/2021

  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced clinical data from two pivotal trials of its anti-PD-1 antibody tislelizumab at the 2021 American Society of Clinical Oncology Annual Meeting.

• BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting

  6/4/2021

  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), today announced that its PARP inhibitor pamiparib showed efficacy in patients with HER2-negative breast cancer and demonstrated numerically higher but not statistically significant progression-free survival in gastric cancer.

• BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021

  6/1/2021

  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that results from the interim analysis of the Phase 3 ALPINE trial comparing BRUKINSA® (zanubrutinib) to ibrutinib in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL

• BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

  5/21/2021

  Tislelizumab combined with chemotherapy demonstrated a statistically significant improvement in progression-free survival at the interim analysis

• BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

  5/19/2021

  Scheduled to present results and trial designs on five therapeutic candidates from 13 clinical trials across eight types of cancer Featuring three anti-PD-1 combinations and the continuing evaluation of next-generation BTK inhibitor zanubrutinib

• BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma

  5/19/2021

  BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA ® (Zanubrutinib) in Marginal Zone Lymphoma

• BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress

  5/12/2021

  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results from its broad hematology program will be presented at the 26 th European Hematology Association 2021 (EHA2021) Virtual Congress being held June 9 – 17, 2021.

• China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer

  5/7/2021

  Pamiparib becomes the first PARP inhibitor approved in both platinum-sensitive and platinum-resistant relapsed ovarian cancer in China

• BeiGene Reports First Quarter 2021 Financial Results

  5/6/2021

  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2021

• 

  Q1 2021: A Look at Biopharma’s Top 25 Companies by Market Cap

  5/3/2021

  BioSpace takes an in-depth look at the Top 25 of Q1.

• BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation

  4/28/2021

  BRUKINSA ® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia

• 

  Clinical Catch-Up: April 12-16

  4/19/2021

  It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.

• BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021

  4/12/2021

  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced results from a planned interim analysis of the Phase 3 RATIONALE 303 trial of its anti-PD-1 antibody tislelizumab compared to docetaxel as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer

• BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

  4/11/2021

  The combination showed preliminary antitumor activity in patients with unresectable or metastatic melanoma refractory or resistant to PD-1/L1 inhibitors and platinum-resistant ovarian cancer in an ongoing Phase 1b clinical trial, with a generally well-tolerated safety profile.

• BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress

  4/8/2021

  Trial did not meet the co-primary efficacy endpoints; no new safety signals identified